Ubs Oconnor LLC Adaptive Biotechnologies Corp Transaction History

Ubs Oconnor LLC

$1.51 Billion
Q4 2024

A detailed history of Ubs Oconnor LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Ubs Oconnor LLC holds 213,829 shares of ADPT stock, worth $1.77 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

213,829

Holding current value

$1.77 Million

% of portfolio

0.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.37 - $6.78 $212,185 - $329,202	48,555 Added 29.38%	213,829 $1.28 Million
Q3 2024 Nov 14, 2024	BUY	$3.37 - $5.12 $335,412 - $509,588	99,529 Added 151.39%	165,274 $846,000
Q1 2024 May 15, 2024	SELL	$2.88 - $4.8 $288,000 - $480,000	-100,000 Reduced 60.33%	65,745 $211,000
Q4 2023 Feb 14, 2024	SELL	$3.46 - $5.33 $123,158 - $189,721	-35,595 Reduced 17.68%	165,745 $812,000
Q3 2023 Nov 14, 2023	BUY	$5.07 - $8.44 $7,605 - $12,660	1,500 Added 0.75%	201,340 $1.1 Million
Q2 2023 Aug 14, 2023	BUY	$6.19 - $8.78 $1.24 Million - $1.75 Million	199,840 New	199,840 $1.34 Billion
Q1 2023 May 15, 2023	BUY	$7.8 - $10.11 $198,931 - $257,845	25,504 Added 16.66%	178,586 $1.58 Million
Q4 2022 Feb 14, 2023	BUY	$6.26 - $9.34 $60,045 - $89,589	9,592 Added 6.68%	153,082 $0
Q3 2022 Nov 14, 2022	SELL	$6.5 - $12.67 $455,000 - $886,900	-70,000 Reduced 32.79%	143,490 $1.02 Billion
Q2 2022 Aug 12, 2022	BUY	$6.4 - $14.73 $803,136 - $1.85 Million	125,490 Added 142.6%	213,490 $1.73 Million
Q1 2022 May 16, 2022	BUY	$10.12 - $28.9 $890,559 - $2.54 Million	88,000 New	88,000 $1.22 Million

Others Institutions Holding ADPT

# of Institutions

225

Shares Held

146M

Call Options Held

19.6K

Put Options Held

27.2K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $1.18B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account